Hilltop National Bank Buys Shares of 13,705 Sanofi $SNY

Hilltop National Bank purchased a new stake in Sanofi (NASDAQ:SNY) during the 2nd quarter, Holdings Channel reports. The institutional investor purchased 13,705 shares of the company’s stock, valued at approximately $662,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Accent Capital Management LLC acquired a new stake in Sanofi in the first quarter valued at $29,000. Eastern Bank raised its stake in shares of Sanofi by 121.0% in the 1st quarter. Eastern Bank now owns 548 shares of the company’s stock valued at $30,000 after purchasing an additional 300 shares in the last quarter. Banque Transatlantique SA acquired a new stake in Sanofi during the first quarter valued at approximately $33,000. Golden State Wealth Management LLC raised its stake in Sanofi by 619.3% during the first quarter. Golden State Wealth Management LLC now owns 633 shares of the company’s stock valued at $35,000 after buying an additional 545 shares in the last quarter. Finally, Brentview Investment Management LLC acquired a new stake in Sanofi during the first quarter valued at approximately $42,000. 14.04% of the stock is owned by institutional investors and hedge funds.

Sanofi Price Performance

Shares of NASDAQ SNY opened at $50.90 on Friday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.94. Sanofi has a 1-year low of $44.62 and a 1-year high of $60.12. The business’s fifty day moving average price is $48.19 and its two-hundred day moving average price is $50.09. The firm has a market capitalization of $124.99 billion, a PE ratio of 12.24, a P/E/G ratio of 1.19 and a beta of 0.51.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Thursday, July 31st. The company reported $0.90 earnings per share for the quarter, missing analysts’ consensus estimates of $0.96 by ($0.06). Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The firm had revenue of $11.34 billion during the quarter, compared to analyst estimates of $9.91 billion. During the same period last year, the business earned $1.73 EPS. The firm’s revenue was down 7.0% on a year-over-year basis. On average, research analysts expect that Sanofi will post 4.36 EPS for the current year.

Analyst Ratings Changes

SNY has been the topic of several research reports. Weiss Ratings reissued a “hold (c)” rating on shares of Sanofi in a research report on Saturday, September 27th. Wall Street Zen raised shares of Sanofi from a “hold” rating to a “buy” rating in a report on Saturday, August 2nd. Barclays reissued an “overweight” rating on shares of Sanofi in a report on Wednesday, July 2nd. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a research note on Tuesday, September 2nd. Finally, JPMorgan Chase & Co. upgraded shares of Sanofi from a “neutral” rating to an “overweight” rating in a research note on Friday, August 8th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $62.67.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.